23Andme控股有限公司：Cd200作爲潛在生物標記物與23Me-00610單藥治療療效

快訊 · 06/03 20:02

23Andme Holding Co.: Tumor Cd200 Is Emerging as a Potential Biomarker Associated With 23Me-00610 Monotherapy Efficacy

23Andme控股有限公司：Cd200作爲潛在生物標記物與23Me-00610單藥治療療效相關。